Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000139:chemically induced; D014227:Triazines / Q000008:administration & dosage / Q000633:toxicity*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D014227:Triazines; C028786:teroxirone